CSL Seqirus Products
See the complete list of all products marketed by CSL Seqirus worldwide.
See Product ListSearch Results
291 results found-
CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season - Jul 17, 2023
https://newsroom.csl.com/2023-07-17-CSL-Seqirus-Begins-Shipping-Portfolio-of-Innovative-Influenza-Vaccines-for-the-2023-24-U-S-Season -
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults - Nov 28, 2023
https://newsroom.csl.com/2023-11-28-Japans-Ministry-of-Health,-Labour-and-Welfare-Approves-CSL-and-Arcturus-Therapeutics-ARCT-154,-the-first-Self-Amplifying-mRNA-vaccine-approved-for-COVID-in-adults -
CSL Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-manufacturing/csl-seqirus-manufacturing-technologies -
There's still a long way to go and our first priority resolutely remains the safety and efficacy of the vaccines we produce.
https://newsroom.csl.com/2020-11-08-CSL-Commences-Manufacturing-of-University-of-Oxford-AstraZeneca-Vaccine-Candidate-in-Melbourne -
Doctors and pharmacists can help prevent illnesses and deaths by clearly explaining the benefits of vaccines, officials at the U.S. Food and Drug Administration recently wrote in the Journal of the American Medical Association.
https://www.csl.com/we-are-csl/vita-original-stories/2024/fda-leaders-sound-the-alarm-about-us-vaccination-trends -
ARCT ) is currently developing next generation mRNA vaccines.
https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology -
Nature recently talked with CSL’s Roberta Duncan and other experts in the field to explain the innovation of self-amplifying mRNA, a new type of vaccine that instructs the body to make more mRNA and protein to boost the immune response.
https://www.csl.com/we-are-csl/vita-original-stories/2024/the-journal-nature-explores-self-amplifying-mrna -
CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
https://www.csl.com/research-and-development/product-pipeline -
CSL Seqirus is a global influenza vaccine provider developing innovative solutions.
https://www.csl.com/patients-public-health/vaccines